1 Result: Comerica
Mirati Therapeutics' KRAZATI Faces Setback; Comerica Q2 Earnings Beat
July 21st, 2023
Mirati Therapeutics, Inc. (Nasdaq: MRTX) faced a setback when the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for its dr. Read more
Load More Content




Member Login